A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

NCT07313891 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped This study has been incorporated into the Relmada REL-NDV01-303 study.

Conditions

Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Bladder (Urothelial, Transitional Cell) Cancer
Urothelial Carcinoma Bladder
Urologic Cancer

Interventions

DRUG: NDV-01 (sustained-release gemcitabine-docetaxel)

Sponsor

Relmada Therapeutics, Inc.